Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein Hertzel C.; Colhoun Helen M.; Dagenais Gilles R.; Diaz Rafael; Lakshmanan Mark; Pais Prem; Probstfield Jeffrey; Botros Fady T.; Riddle Matthew C.; Ryden Lars; Xavier Denis; Atisso Charles Messan; Dyal Leanne; Hall Stephanie; Rao-Melacini Purnima; Wong Gloria; Avezum Alvaro; Basile Jan; Chung Namsik; Conget Ignacio; Cushman William C.; Franek Edward; Hancu Nicolae; Hanefeld Markolf; Holt Shaun; Jansky Petr; Keltai Matyas; Lanas Fernando; Leiter Lawrence A.; Lopez-Jaramillo Patricio; Cardona Munoz Ernesto German; Pirags Valdis; Pogosova Nana; Raubenheimer J.; Shaw Jonathan E.; Sheu Wayne H-H; Temelkova-Kurktschiev Theodora

首页> 外文期刊>The Lancet >Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

【24h】

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

机译：2型糖尿病患者的杜拉格尔蛋白质和肾果糖：对倒带随机，安慰剂对照试验的探索性分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulaglutide on renal outcomes in an exploratory analysis of the REWIND trial of the effect of dulaglutide on cardiovascular disease.

机译：背景技术两种胰高血糖素类肽-1（GLP-1）受体激动剂在患有2型糖尿病的人的肾脏结果下降，患有心血管疾病的风险。我们评估了GLP-1受体激动剂杜拉格拉蛋白对抗风蛋白酶效果对心血管疾病效果的探索性分析中的肾果菌的长期效果。

著录项

来源
《The Lancet》 |2019年第10193期|共8页
作者
Gerstein Hertzel C.; Colhoun Helen M.; Dagenais Gilles R.; Diaz Rafael; Lakshmanan Mark; Pais Prem; Probstfield Jeffrey; Botros Fady T.; Riddle Matthew C.; Ryden Lars; Xavier Denis; Atisso Charles Messan; Dyal Leanne; Hall Stephanie; Rao-Melacini Purnima; Wong Gloria; Avezum Alvaro; Basile Jan; Chung Namsik; Conget Ignacio; Cushman William C.; Franek Edward; Hancu Nicolae; Hanefeld Markolf; Holt Shaun; Jansky Petr; Keltai Matyas; Lanas Fernando; Leiter Lawrence A.; Lopez-Jaramillo Patricio; Cardona Munoz Ernesto German; Pirags Valdis; Pogosova Nana; Raubenheimer J.; Shaw Jonathan E.; Sheu Wayne H-H; Temelkova-Kurktschiev Theodora;
展开▼
作者单位

McMaster Univ Populat Hlth Res Inst Hamilton ON L8S 4K1 Canada;

Univ Edinburgh Edinburgh Midlothian Scotland;

Univ Laval Inst Univ Cardiol &

Pneumol Quebec City PQ Canada;

Estudios Clin Latinoamer ECLA Rosario Santa Fe Argentina;

Eli Lilly &

Co Indianapolis IN 46285 USA;

St Johns Res Inst Bangalore Karnataka India;

Univ Washington Dept Med Seattle WA USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Oregon Hlth &

Sci Univ Dept Med Portland OR 97201 USA;

Karolinska Inst Dept Med K2 Stockholm Sweden;

St Johns Res Inst Bangalore Karnataka India;

Eli Lilly &

Co Indianapolis IN 46285 USA;

McMaster Univ Populat Hlth Res Inst Hamilton ON L8S 4K1 Canada;

McMaster Univ Populat Hlth Res Inst Hamilton ON L8S 4K1 Canada;

McMaster Univ Populat Hlth Res Inst Hamilton ON L8S 4K1 Canada;

McMaster Univ Populat Hlth Res Inst Hamilton ON L8S 4K1 Canada;

Inst Dante Pazzanese Cardiol Sao Paulo Brazil;

Med Univ South Carolina Charleston SC 29425 USA;

Yonsei Univ Hlth Syst Seoul South Korea;

Hosp Clin &

Univ Endocrinol &

Nutr Dept Barcelona Spain;

Memphis Vet Affairs Med Ctr Memphis TN USA;

Polish Acad Sci Mossakowski Med Res Ctr Warsaw Poland;

Iuliu Hatieganu Univ Med &

Pharm Cluj Napoca Romania;

Tech Univ Dresden Dept Internal Med Dresden Germany;

Victoria Univ Wellington Wellington New Zealand;

Univ Hosp Motol Prague Czech Republic;

Semmelweis Univ Hungarian Inst Cardiol Budapest Hungary;

Univ La Frontera Temuco Chile;

Univ Toronto St Michaels Hosp Li Ka Shing Knowledge Inst Toronto ON Canada;

Univ Santander UDES FOSCAL Res Inst Bucaramanga Colombia;

Univ Guadalajara Ctr Univ Ciencias Salud Guadalajara Jalisco Mexico;

Latvijas Univ Riga Latvia;

Natl Med Res Ctr Cardiol Moscow Russia;

Univ Cape Town Cape Town South Africa;

Baker Heart &

Diabet Inst Melbourne Vic Australia;

Taichung Vet Gen Hosp Taichung Taiwan;

Robert Koch Med Ctr Sofia Bulgaria;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial [J] . Gerstein Hertzel C., Colhoun Helen M., Dagenais Gilles R., The Lancet . 2019,第10193期

机译：2型糖尿病患者的杜拉格尔蛋白质和肾果糖：对倒带随机，安慰剂对照试验的探索性分析
2. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial [J] . Muskiet Marcel H. A., Tonneijck Lennart, Huang Yao, The lancet. Diabetes & endocrinology. . 2018,第11期

机译：2型糖尿病和急性冠状动脉综合征患者的Lixisenatide和肾果糖：Elixa随机，安慰剂对照试验的探索性分析
3. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial [J] . Cherney David Z. I., Zinman Bernard, Inzucchi Silvio E., The lancet. Diabetes & endocrinology. . 2017,第8期

机译：Empagliflozin对2型糖尿病患者尿白霉素对肌酐比例的影响及成熟的心血管疾病：EMPA-REG结果随机，安慰剂对照试验的探索性分析
4. Randomised Controlled Trial of an In-Home Monitoring Intervention to Improve Health Outcomes for Type 2 Diabetes: Study Protocol [C] . Karen CARLISLE, Robin WARREN, Paul SCUFFHAM, Global Telehealth (Conference) . 2012

机译：随机对照试验的内部监测干预以改善2型糖尿病的健康结果：研究方案
5. A randomized placebo-controlled trial of pioglitazone to improve metabolic control in adolescents with type 1 diabetes mellitus. [D] . Zdravkovic, Vera. 2005

机译：吡格列酮对改善1型糖尿病青少年的代谢控制的随机安慰剂对照试验。
6. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis [O] . Gilles R. Dagenais, Lars Rydén, Lawrence A. Leiter, 2020

机译：患有2型糖尿病和心血管危险因素的人的总心血管或致命事件在倒带跟踪中用杜拉格利德治疗：HOC分析
7. Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial [O] . G Ferrannini, H.C Gerstein, H.M Colhoun, 2020

机译：杜拉加仑在糖尿病患者和冠状动脉血管疾病的患者患者中有或没有背景二甲双胍，患者的心脏保护剂。倒带试验的子组分析

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

摘要

著录项

相似文献

相关主题

期刊订阅